Skip to main content

View full-text article in PMC

. 2017 Apr 24;10:87. doi: 10.1186/s13045-017-0456-5

Table 2.

Selected completed immunotherapy trials in treatment-naïve NSCLC

Completed trial name	Phase	Histology	Therapy	mORR (%)	<1% PD-L1 ORR	>1% PD-L1 ORR	>50% PD-L1 ORR	<1% PD-L1 PFS	>1% PD-L1 PFS	>50% PD-L1 PFS	Ref
CheckMate 012	1	ALL	NIVO3	23	14	28	50	6.6	3.5	8.4	[18, 19]
			NIVO3 + IPIQ12W	47	30	57	100	4.7	8.1	13.6
			NIVO3 + IPIQ6W	39	0	57	86	2.4	10.6	NR
Trial Name	Phase	Histology	Therapy	PFS (months)	6-month OS (%)	ORR (%)	DOR	TrAEs (%)	3 + TrAEs (%)
KEYNOTE-024	3	≥50% PD-L1	PEMBROQ3W	10.3	80.2	44.8	NR	73.4	26.6		[21]
KEYNOTE-024	3	≥50% PD-L1	PT-DC	6.0	72.4	27.8	6.3months	90.0	53.3		[21]
Trial name	Phase	Histology	Therapy	PFS (months)	OS	ORR	DOR	TrAEs (%)	3 + TrAEs (%)
CheckMate 026	3	≥5% PD-L1	NIVO3	4.2	pending	pending	pending	71	18		[60]
CheckMate 026	3	≥5% PD-L1	PT-DC	5.9	pending	pending	pending	92	51